Insider Buying: Avantor (NYSE:AVTR) Director Purchases $458,000.00 in Stock

Avantor, Inc. (NYSE:AVTR) Director Gregory Lucier acquired 50,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were bought at an average cost of $9.16 per share, with a total value of $458,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at $458,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Avantor Trading Down 0.7%

NYSE:AVTR opened at $9.05 on Thursday. Avantor, Inc. has a 12-month low of $8.83 and a 12-month high of $18.02. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.70. The stock’s 50 day simple moving average is $11.06 and its 200-day simple moving average is $12.05. The firm has a market cap of $6.17 billion, a P/E ratio of -11.60, a PEG ratio of 3.59 and a beta of 0.94.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.01. The firm had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. Avantor had a positive return on equity of 10.45% and a negative net margin of 8.09%.The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the company earned $0.27 earnings per share. Avantor has set its FY 2026 guidance at 0.770-0.830 EPS. Equities analysts anticipate that Avantor, Inc. will post 1.06 EPS for the current year.

Hedge Funds Weigh In On Avantor

Several hedge funds have recently bought and sold shares of the company. Sector Gamma AS grew its stake in Avantor by 28.0% in the 3rd quarter. Sector Gamma AS now owns 477,104 shares of the company’s stock valued at $5,954,000 after acquiring an additional 104,466 shares during the last quarter. Greenhaven Associates Inc. acquired a new position in Avantor during the third quarter worth about $228,528,000. Voss Capital LP purchased a new stake in shares of Avantor in the second quarter valued at about $6,057,000. ABS Direct Equity Fund LLC acquired a new stake in shares of Avantor in the third quarter valued at approximately $1,248,000. Finally, Tredje AP fonden grew its position in shares of Avantor by 110.7% in the second quarter. Tredje AP fonden now owns 110,981 shares of the company’s stock valued at $1,494,000 after purchasing an additional 58,304 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $10.50 price target on shares of Avantor in a research note on Thursday, February 12th. Citigroup dropped their target price on Avantor from $13.00 to $11.00 and set a “neutral” rating on the stock in a research report on Thursday, February 12th. Robert W. Baird set a $11.00 target price on Avantor in a research note on Thursday, February 12th. Jefferies Financial Group restated an “underperform” rating and issued a $8.00 price target on shares of Avantor in a research note on Thursday, February 12th. Finally, Morgan Stanley set a $10.00 price objective on Avantor in a report on Friday, February 13th. Three investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $11.83.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.